NCT00685529View on ClinicalTrials.gov

Study of Arformoterol Tartrate Inhalation Solution and Racemic Formoterol in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

October 31, 2005

Study Completion Date

October 31, 2005

Conditions
COPD
Interventions
DRUG

Racemic formoterol

12 µg of racemic formoterol fumarate BID

DRUG

Arformoterol tartrate inhalation solution

15 µg of nebulized arformoterol tartrate inhalation solution BID

DRUG

Racemic formoterol

24 µg of racemic formoterol fumarate BID

Trial Locations (6)

Unknown

Long Beach

Fort Lauderdale

Raleigh

Simpsonville

Spartanburg

Spokane

All Listed Sponsors
lead

Sumitomo Pharma America, Inc.

INDUSTRY

NCT00685529 - Study of Arformoterol Tartrate Inhalation Solution and Racemic Formoterol in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter | Biotech Hunter